Everything below concerns LC-MS/MS. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Verification of research-grade material depends on documentation supplied with a sample. A certificate of analysis lists purity, identity, and the methods used to establish each value. Buyers comparing suppliers look at chromatographic purity figures, mass confirmation data, and whether methods are described in enough detail to be reproduced. Independent testing can confirm reported values but adds cost and time. Because the research chemical market is not uniformly regulated, provenance and documentation quality vary widely, and claims should be evaluated against raw data rather than summary labels.
Characterization of retatrutide in research settings relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase separation resolves the parent peptide from related impurities, while electrospray ionization mass spectrometry confirms molecular mass against a calculated value. Peptide mapping after enzymatic digestion can verify the amino acid sequence. Laboratories often combine orthogonal methods because no single technique establishes both identity and purity. Detected impurities typically include truncated sequences, oxidized residues, and deamidated forms that arise during synthesis or storage.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
==== Pollybeak ==== The "pollybeak" deformity, characterized by excessive supratip fullness usually involving a cartilaginous hump or loss of tip projection, is the indication for approximately 50% of all revision rhinoplasties. If too much of the osseo-cartilaginous framework is removed, the consequent weakening can cause the external nasal skin to become shapeless, resulting in a "pollybeak" deformity, resembling the beak of a parrot.
Model editing techniques also exist in computer vision. Finally, some have argued that the opaqueness of AI systems is a significant source of risk and better understanding of how they function could prevent high-consequence failures in the future. "Inner" interpretability research aims to make ML models less opaque. One goal of this research is to identify what the internal neuron activations represent. For example, researchers identified a neuron in the CLIP artificial intelligence system that responds to images of people in Spider-Man costumes, sketches of Spider-Man, and the word 'spider'. It also involves explaining connections between these neurons or 'circuits'. For example, researchers have identified pattern-matching mechanisms in transformer attention that may play a role in how language models learn from their context. "Inner interpretability" has been compared to neuroscience. In both cases, the goal is to understand what is going on in an intricate system, though ML researchers have the benefit of being able to take perfect measurements and perform arbitrary ablations.
== Manufacture == Almost all products rich in protein are suitable for the production of HVP. Today, it is made mainly from protein resources of vegetable origin, such as defatted oil seeds (soybean meal, grapeseed meal) and protein from maize (Corn gluten meal), wheat (gluten), pea, and rice. The process and the feedstock determines the organoleptic properties of the end product. Proteins consist of chains of amino acids joined through amide bonds. When subjected to hydrolysis (hydrolyzed), the protein is broken down into its component amino acids. In aHVP, hydrochloric acid is used for hydrolysis. The remaining acid is then neutralized by mixing with an alkali such as sodium hydroxide, which leaves behind table salt, which comprises up to 20% of the final product (acid-hydrolyzed vegetable protein, aHVP). In enzymatic HVP (eHVP), proteases are used to break down the proteins under a more neutral pH and lower temperatures. The amount of salt is greatly reduced. Because of the different processing conditions, the two types of HVP have different sensory profiles. aHVP is usually dark-brown in color and has a strong savory flavor, whereas eHVP usually is lighter in color and has a mild savory flavor.
== Factors that affect biomembranes and lipid formations == There are two basic terms used to describe lipid phases: lamellar and non-lamellar phases. Lipids can undergo polymorphic or mesomorphic changes leading to the formation of lamellar or non-lamellar phases. Various factors can affect the overall function of the biomembrane and decrease its ability to function as a protective barrier and maintained the order of the inner components. The bilayer thickness, surface charge, intermolecular forces, amphiphilic molecules, changes in free energy, alternating or spontaneous curvatures, increase or decrease in temperature, solvents, and the environment are all examples of different conditions that cause changes in biomembranes. For example, the strength of the intermolecular forces within the biomembrane are fairly strong but when lipids are extracted from biomembranes for analytical purposes there is a decrease in the constraints by the intermolecular forces against the phospholipids which may cause the lipid to undergo polymorphism as well as a temporary rearrangement of other lipids or proteins in the biomembrane. The thickness of the biomembrane determines the permeability of the membrane and ethanol, which can be used as a solvent, is able to reduce the thickness of the biomembrane which is one way this amphiphilic molecule is able to permeate through the biomembrane. There can also be free energy changes that can increase or decrease during the phase transitions of the phospholipids during polymorphism or mesomorphism which can also affect the curvature of lipids.
=== 2018 American consulate bombing === On 2 December 2018, at approximately 7:30 CST, two grenades were thrown onto consular grounds in Guadalajara, with one of them exploding and causing a 16-inch (approximately 40 cm) hole in the wall of the building. At the time of the bombing, the consulate general office was closed and no injuries were sustained. It is unconfirmed if the attack was carried out by a cartel.
Sources: en.wikipedia.org
==== Corona treatment ==== Corona treatment is a surface modification method using a low temperature corona discharge to increase the surface energy of a material, often polymers and natural fibers. Most commonly, a thin polymer sheet is rolled through an array of high-voltage electrodes, using the plasma created to functionalize the surface. The limited penetration depth of such treatment provides vastly improved adhesion while preserving bulk mechanical properties. Commercially, corona treatment has been used widely for improved dye adhesion before printing text and images on plastic packaging materials. The hazardous nature of remnant ozone after corona treatment stipulates careful filtration and ventilation during processing, restricting its implementation to applications with strict catalytic filtered systems. This limitation prevents widespread use within open-line manufacturing processes Several factors influence the efficiency of the flame treatment such as air-to-gas ratio, thermal output, surface distance, and oxidation zone dwell time. Upon conception of the process, a corona treatment immediately followed film extrusions, but the development of careful transportation techniques allows treatment at an optimized location. Conversely, in-line corona treatments have been implemented into full-scale production lines such as those in the newspaper industry. These in-line solutions are developed to counteract the decrease in wetting characteristics caused by excessive solvent use.
E300 ascorbic acid (approved for use as a food additive in the UK, US Canada, Australia and New Zealand) E301 sodium ascorbate (approved for use as a food additive in the UK, US, Canada, Australia and New Zealand) E302 calcium ascorbate (approved for use as a food additive in the UK, US Canada, Australia and New Zealand) E303 potassium ascorbate (approved in Australia and New Zealand, but not in the UK, US or Canada) E304 fatty acid esters of ascorbic acid such as ascorbyl palmitate (approved for use as a food additive in the UK, US, Canada, Australia and New Zealand) The stereoisomers of Vitamin C have a similar effect in food despite their lack of efficacy in human scurvy. They include erythorbic acid and its sodium salt (E315, E316).
Schröder (1993, 2002) reviewed the issue of CPA dosage and recommended a dosage of 200 to 300 mg/day for CPA as a monotherapy and a dosage of 100 to 200 mg/day for CPA in combined androgen blockade (that is, CPA in combination with surgical or medical castration). However, the combination of CPA with castration for prostate cancer has been found to significantly decrease overall survival compared to castration alone. Hence, the use of CPA as the antiandrogen component in combined androgen blockade would appear not to be advisable. When used by intramuscular injection to treat prostate cancer, CPA is used at a dosage of 300 mg once a week. The combination of CPA with an estrogen such as ethinylestradiol sulfonate or low-dose diethylstilbestrol has been used as a form of combined androgen blockade and as an alternative to the combination of CPA with surgical or medical castration.
Finally, rapG and rapH have been identified to code for enzymes that have a positive regulatory role in the preparation of rapamycin through the control of rapamycin PKS gene expression. Biosynthesis of this 31-membered macrocycle begins as the loading domain is primed with the starter unit, 4,5-dihydroxocyclohex-1-ene-carboxylic acid, which is derived from the shikimate pathway. Note that the cyclohexane ring of the starting unit is reduced during the transfer to module 1. The starting unit is then modified by a series of Claisen condensations with malonyl or methylmalonyl substrates, which are attached to an acyl carrier protein (ACP) and extend the polyketide by two carbons each. After each successive condensation, the growing polyketide is further modified according to enzymatic domains that are present to reduce and dehydrate it, thereby introducing the diversity of functionalities observed in rapamycin (figure 1). Once the linear polyketide is complete, L-pipecolic acid, which is synthesized by a lysine cycloamidase from an L-lysine, is added to the terminal end of the polyketide by an NRPS. Then, the NSPS cyclizes the polyketide, giving prerapamycin, the first enzyme-free product. The macrocyclic core is then customized by a series of post-PKS enzymes through methylations by MTases and oxidations by P-450s to yield rapamycin.
Sources: en.wikipedia.org
An autoradiograph is an image on an X-ray film or nuclear emulsion produced by the pattern of decay emissions (e.g., beta particles or gamma rays) from a distribution of a radioactive substance. Alternatively, the autoradiograph is also available as a digital image (digital autoradiography), due to the recent development of scintillation gas detectors or rare-earth phosphorimaging systems. The film or emulsion is apposed to the labeled tissue section to obtain the autoradiograph (also called an autoradiogram). The auto- prefix indicates that the radioactive substance is within the sample, as distinguished from the case of historadiography or microradiography, in which the sample is marked using an external source. Some autoradiographs can be examined microscopically for localization of silver grains (such as on the interiors or exteriors of cells or organelles) in which the process is termed micro-autoradiography. For example, micro-autoradiography was used to examine whether atrazine was being metabolized by the hornwort plant or by epiphytic microorganisms in the biofilm layer surrounding the plant.
=== Plasticity === In addition to having a genetic basis, the composition of muscle fiber types is flexible and can vary with a number of different environmental factors. This plasticity can, arguably, be the strongest evolutionary advantage among organisms with muscle. In fish, different fiber types are expressed at different water temperatures. Cold temperatures require more efficient metabolism within muscle and fatigue resistance is important. While in more tropical environments, fast powerful movements (from higher fast-twitch proportions) may prove more beneficial in the long run. In rodents such as rats, the transitory nature of their muscle is highly prevalent. They have high percentage of hybrid muscle fibers and have up to 60% in fast-to-slow transforming muscle. Environmental influences such as diet, exercise and lifestyle types have a pivotal role in proportions of fiber type in humans. Aerobic exercise will shift the proportions towards slow twitch fibers, while explosive powerlifting and sprinting will transition fibers towards fast twitch. In animals, "exercise training" will look more like the need for long durations of movement or short explosive movements to escape predators or catch prey.
This formula was developed by Levey et al. The 2009 CKD-EPI formula was suggested to improve cardiovascular risk prediction over the MDRD Study formula in a middle-age population. The 2021 CKD-EPI formula does not include a race coefficient (see discussion below). The 2021 CKD-EPI equation is:
== General mammalian research == Migliaro Petroni et al. (2026) describe tracks of a small-bodied, fast-moving mammal from the Upper Cretaceous (Maastrichtian) strata of the Yacoraite Formation (Argentina), assigned to the ichnotaxon Brasilichnium cf. saltatorium and extending known stratigraphic distribution of the ichnogenus Brasilichnium. A new, diverse assemblage of teeth of Paleocene (Torrejonian) mammals is reported from the Tullock Member of the Fort Union Formation (Montana, United States) by Hovatter & Wilson Mantilla (2026). Evidence indicating that carbon isotope excursions and probable warming events during the Danian were associated with strong pulses of turnover of mammalian assemblages is reported from the study of the fossil record from the San Juan Basin (New Mexico, United States) and other basins in the Rocky Mountain Region is presented by Secord et al. (2026). Evidence from the study of teeth of Paleocene placentals from the Nanxiong, Qianshan and Chijiang basins (China), indicating that the studied mammals achieved high dental topographic variability during the first 10 million years of the Cenozoic and that the variability of their dental traits paralleled global and regional environmental changes, is presented by Tseng, Li & Ting (2026), who argue that living placental lineages might originate from phenotypically variable and functionally flexible ancestors such as the mammals from the studied assemblages from paleotropical Asia.
Stable isotope labeling by amino acids in cell culture (SILAC) is a technique based on mass spectrometry that detects differences in protein abundance among samples using non-radioactive isotopic labeling. It is a popular method for quantitative proteomics.
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
Trials measure percentage change in body weight, absolute weight loss, and glycemic markers such as hemoglobin A1c. They also record blood pressure, lipids, and liver fat. Adverse events are tracked throughout.